Cystic Fibrosis Canada News Hub
Stay updated with the latest cystic fibrosis news and trending topics from Canada and around the world. In this News Hub, you'll find information on Cystic Fibrosis Canada's programs and initiatives, and news relating to cystic fibrosis research, policies, treatment and community activities.
Search News posts by topics or add text to search for specific articles.
Cystic Fibrosis Canada's 2023-2024 Impact Report
The team at Cystic Fibrosis Canada is pleased to share our 2023-24 Impact Report. Entitled Forward Together, it summarizes the accomplishments of the past year as we work with the Canadian cystic fibrosis community to make longer, healthier and fuller lives a reality for all Canadians with cystic fibrosis.
Our progress in 2023-24 reflects that we are at a crossroads in cystic fibrosis. Responding to the realities of CF today and preparing for the needs of tomorrow means there is much work still to be done. But there is also much to celebrate.
Read the reportSearch and Filter News
Exploring new research ideas in cystic fibrosis
Cystic Fibrosis Canada invests $250,000 in innovative projects that respond to unmet needs.
Cystic Fibrosis Canada awards 69 community members for their dedication and leadership
Cystic Fibrosis Canada is pleased to recognize 69 community members across the country who have contributed to the work of the organization and made meaningful impact in the lives of people affected by the disease.
2024: Celebrating the incredible achievements made possible by you
Thanks to your support in 2024, we raised over $3 million, advanced research, and secured better access to treatments for Canadians with CF. Here's to even more progress in 2025!
Growing evidence of Trikafta’s benefit
CIHI’s report reveals Trikafta’s impact on reducing acute care needs for Canadians with CF, while highlighting access inequities and ongoing challenges in care.
Trikafta funding recommendation for rare cystic fibrosis mutations brings hope to some, but falls short for others, says Cystic Fibrosis Canada
Canada’s Drug Agency recommends funding Trikafta for 152 rare CF mutations, aiding 240 Canadians. Cystic Fibrosis Canada calls for immediate access and inclusion for all who could benefit.
Keeping up with the changing state of cystic fibrosis
Cystic Fibrosis Canada receives Canadian Drug Agency funding to continue strengthening the Canadian Cystic Fibrosis Registry.
Let’s Ensure the Right to Try for Everyone with CF
Today, we are calling on you to help us. Please join us in supporting the basic right for everyone with CF to try life-changing treatments.
Cystic Fibrosis Canada Celebrates Approval of Trikafta for Rare Mutations
Cystic Fibrosis Canada is encouraged by a recent decision by Health Canada to approve the life-changing cystic fibrosis (CF) drug Trikafta for some living with rare mutations that lead to CF.
Research Competition Tackles Rare CFTR Mutations
It is with great enthusiasm that Génome Québec and Cystic Fibrosis Canada announce the launch of the Tackle Rare, Orphan CFTR Mutations Competition.
Frank Leier 100th Birthday
Frank Leier, also known as "Mr. Saskatchewan," recently turned 100! Celebrated for his lifelong contributions to the CF community, Frank has been a pivotal figure in CF advocacy and fundraising.
2024 Research Competition
Cystic Fibrosis Canada has opened its annual grant competition for 2024.
Trikafta funding for 2 to 5-year-olds
Trikafta is now available to Canadians aged two years and older, with at least one F508del gene mutation, through publicly funded drug plans in all but two jurisdictions, the Yukon and Northwest Territories.
- 1
- 2
- 3
- 4
Exploring new research ideas in cystic fibrosis
Cystic Fibrosis Canada invests $250,000 in innovative projects that respond to unmet needs.
Cystic Fibrosis Canada awards 69 community members for their dedication and leadership
Cystic Fibrosis Canada is pleased to recognize 69 community members across the country who have contributed to the work of the organization and made meaningful impact in the lives of people affected by the disease.
2024: Celebrating the incredible achievements made possible by you
Thanks to your support in 2024, we raised over $3 million, advanced research, and secured better access to treatments for Canadians with CF. Here's to even more progress in 2025!
Growing evidence of Trikafta’s benefit
CIHI’s report reveals Trikafta’s impact on reducing acute care needs for Canadians with CF, while highlighting access inequities and ongoing challenges in care.
Trikafta funding recommendation for rare cystic fibrosis mutations brings hope to some, but falls short for others, says Cystic Fibrosis Canada
Canada’s Drug Agency recommends funding Trikafta for 152 rare CF mutations, aiding 240 Canadians. Cystic Fibrosis Canada calls for immediate access and inclusion for all who could benefit.
Keeping up with the changing state of cystic fibrosis
Cystic Fibrosis Canada receives Canadian Drug Agency funding to continue strengthening the Canadian Cystic Fibrosis Registry.
Let’s Ensure the Right to Try for Everyone with CF
Today, we are calling on you to help us. Please join us in supporting the basic right for everyone with CF to try life-changing treatments.
Cystic Fibrosis Canada Celebrates Approval of Trikafta for Rare Mutations
Cystic Fibrosis Canada is encouraged by a recent decision by Health Canada to approve the life-changing cystic fibrosis (CF) drug Trikafta for some living with rare mutations that lead to CF.
Research Competition Tackles Rare CFTR Mutations
It is with great enthusiasm that Génome Québec and Cystic Fibrosis Canada announce the launch of the Tackle Rare, Orphan CFTR Mutations Competition.
Frank Leier 100th Birthday
Frank Leier, also known as "Mr. Saskatchewan," recently turned 100! Celebrated for his lifelong contributions to the CF community, Frank has been a pivotal figure in CF advocacy and fundraising.
2024 Research Competition
Cystic Fibrosis Canada has opened its annual grant competition for 2024.
Trikafta funding for 2 to 5-year-olds
Trikafta is now available to Canadians aged two years and older, with at least one F508del gene mutation, through publicly funded drug plans in all but two jurisdictions, the Yukon and Northwest Territories.
CF Canada Community Forum
CF Canada successfully hosted the virtual CF Canada Community Forum: "Unchartered Territories" on April 26, 2024.
Genome Quebec Research Partnership
It is with great pleasure that Génome Québec and Cystic Fibrosis Canada join forces to create a new funding program to support omics research on cystic fibrosis.
2023-24 Impact Report
The team at Cystic Fibrosis Canada is pleased to share our 2023-24 Impact Report, Forward Together.
Breathless Podcast Launches
Cystic Fibrosis Canada is excited to be making our podcast debut with today’s launch of Breathless. Hosted by Jeremie Saunders, co-host of the Sickboy.
20th Annual Walk on May 26
Cystic Fibrosis Canada’s signature event, the Walk To Make Cystic Fibrosis History is happening on Sunday, May 26 at more than 40 locations across the country.
$2M Invested in CF Research 2024
Cystic Fibrosis Canada today announced a new investment of more than $2 million in research initiatives that align with the Canadian cystic fibrosis (CF) community’s top priorities.
New survival milestone in the 2022 Canadian CF Registry Report
New data released today by Cystic Fibrosis Canada show that life-changing treatments are increasingly reaching the 4,445 Canadians with cystic fibrosis (CF) and that Canadians born with CF today will live longer than those who came before them.
New Survival Milestone
Life-changing treatments are increasingly reaching the 4,445 Canadians with cystic fibrosis (CF) and that Canadians born with CF today will live longer than those who came before them.
$5M Fundraised by Carstar
The Driven Brands collision group announced its monumental North American milestone of raising over $5 million for cystic fibrosis research, care, and advocacy.
Calls for Expanded Funding of Trikafta
Last week, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended that provinces and territories fund the transformational cystic fibrosis drug Trikafta for Canadians aged two and older with at least one F508del gene mutation.
Trikafta Approved for 2 to 5-year-olds
Health Canada has approved the life-changing cystic fibrosis (CF) drug Trikafta for children aged two to five, with at least one F508del gene mutation.
$250K Awarded for Research Grants
Cystic Fibrosis Canada has awarded $250,000 in seed grants to five researchers to encourage new and innovative research projects in support of CF research.
25 Years of Carstar Partnership
Last week at CARSTAR’s annual Evolution Conference in Montreal, Quebec, Cystic Fibrosis Canada and the collision and glass service organization celebrated the milestone of 25 years of partnership.
European CF Conference
Cystic Fibrosis Canada’s Chief Scientific Officer, Dr. Paul Eckford, recently attended the European CF Society’s annual conference where important advances in research and clinical care were shared.
Clinician Recommendations for CFTR Modulators
Cystic Fibrosis Canada’s Healthcare Advisory Council has published recommendations for the follow-up of pregnancies and newborns of mothers who are receiving CFTR modulators, like Trikafta.
$2.7M in New Research Funding
Cystic Fibrosis Canada has awarded nearly $2.7M in research funding to projects that support the organization’s new approach to research funding, aimed at improving health outcomes for people living with cystic fibrosis (CF).
New Standards of Care Guidelines
Cystic Fibrosis Canada’s Healthcare Advisory Council (HAC) has published standardized Canadian care guidelines for the diagnosis and treatment of pulmonary exacerbations in patients with cystic fibrosis.
Cystic Fibrosis Canada's 2022-2023 impact report
We are pleased to share our 2022-2023 Impact Report and celebrate the work our community helped us to achieve on behalf of Canadians with cystic fibrosis.
2022-23 Impact Report
We are pleased to share our 2022-2023 Impact Report and celebrate the work our community helped us to achieve on behalf of Canadians with cystic fibrosis.
19th Annual Walk on May 28
Cystic Fibrosis Canada’s signature event, the Walk To Make Cystic Fibrosis History, happens on Sunday, May 28 at more than 50 locations across the country.
Researchers Look at Priorities for CF Community
Cystic fibrosis researchers come together to tackle priority needs of Canadians living with the disease Cystic Fibrosis Canada’s Broken Arrow Conference kicks off a new approach to balancing patient needs with impactful, high-quality research.
National Rare Disease Strategy
Today, the federal government announced its approach to a 2019 commitment to improve drug access for Canadians with a rare disease, a strategy that Cystic Fibrosis Canada with the Canadian cystic fibrosis (CF) community has long advocated for.
CF Canada Reaccredited by Imagine Canada
Cystic Fibrosis Canada today announces that it has achieved reaccreditation under Imagine Canada’s Standards Program, being an accredited member of the Standard Program since October 1st, 2015.
2021 Registry Report
Today, Cystic Fibrosis Canada released its Canadian Cystic Fibrosis Registry 2021 Annual Data Report. The Canadian Cystic Fibrosis Registry has examined health outcomes for people living with cystic fibrosis (CF) across Canada since the 1970s.
Winnipeg Kin Club Donates $100K
For the second time since 2020, the Kinsmen Club of Winnipeg has made an astounding six-figure donation to Cystic Fibrosis Canada.
National Funding for Trikafta for 6 and up
Effective today, all provinces, territories and federal drug funding programs across Canada are funding the Trikafta for children and adults aged six and older with at least one F508del gene mutation.
Canadian Data on COVID-19 Impact
Cystic Fibrosis Canada has continued its work to contribute to an important global understanding of the impact of COVID-19 on people with cystic fibrosis (CF).
CADTH Paves Way to Trikafta Access
Today, CADTH issued a positive draft recommendation to fund the transformational cystic fibrosis drug, Trikafta, for Canadians aged 6 and older with at least one F508del gene mutation.
$2.1M Invested in Research 2022
Today, Cystic Fibrosis Canada announced it will fund 10 new Canadian research projects aimed at addressing the priorities and improving the health outcomes of people impacted by cystic fibrosis (CF).
2021-22 Impact Report
Cystic Fibrosis Canada is pleased to share the 2021-2022 Impact Report, highlighting the progress that was made possible thanks to our donors and supporters.
18th Annual Walk on May 29
For the first time in two years, Cystic Fibrosis Canada’s signature event, the Walk to Make Cystic Fibrosis History, will return to an in-person format on May 29, while also offering a virtual option
Trikafta Approved for 6 to 11-year-olds
The Canadian cystic fibrosis community is celebrating today as Health Canada approves the life-changing cystic fibrosis drug, Trikafta, for children aged six to 11 with at least one F508del gene mutation.
Changes to PMPRB Improves Access to CF Drugs
The Quebec Court of Appeal has issued a decision in the court case brought forward by a number of pharmaceutical companies on which Cystic Fibrosis Canada intervened.
2020 Registry Report
Today, Cystic Fibrosis Canada released its Canadian Cystic Fibrosis Registry 2020 Annual Data Report.
Trikafta Research Shows Promising Results
Cystic Fibrosis Canada is imploring the government to take action given new research published today that demonstrates that access to the cystic fibrosis (CF) drug Trikafta in 2021 would result in profound health improvements for people living with cystic fibrosis who take the drug. By 2030 Trikafta could reduce the number of people living with severe lung disease by 60% and reduce the number of deaths by 15%.